Mecwins2021-05-05T07:37:25+00:00

Mecwins

Innovating in biotechnology

We think high. We innovate in biotechnology. Together with our in-house expertise, Mecwins applies the latest advancements of Nanotechnology in the Diagnostic field with the mission of helping scientists and physicians to reach the unbelievable. The detection limit achieved with our technology is several order of magnitude better than that achieved in routine clinical practice.

Mecwins logo spain

Learn more about the science behind Mecwins technology

Mecwins uses its own technology based on single molecule digital counting to produce ultrahigh sensitive immunoassays for oncology, cardiovascular, inflammatory and infectious diseases.

Mission

We think high. Together with our in-house expertise, Mecwins applies the latest advancements of Nanotechnology in the Sensors field with the mission of helping scientists and physicians to reach the unbelievable

People

Mecwins team is comprised of experienced scientists and technicians. We aim to combine knowledge and expertise from different fields to provide innovative tools for research and analysis in life sciences. 50% of our team has a PhD degree.

Patent

The World Intellectual Property Organization (WIPO) protects our technology and our innovative method to detect biomolecules. Mecwins possesses exclusive licenses for several patents, since the technology thereby protected is usable in many applications, from microelectronics to biomedicine.

Medical Applications

Mecwins technology is based on a combination of nanomechanical sensing and plasmonic emission with a sandwich immunoassay. The detection limit achieved with our technology is at least one million lower than that achieved in routine clinical practice.

Discover

Scientific Instrumentation

Mecwins technology is based on a combination of nanomechanical sensing and plasmonic emission with a sandwich immunoassay. The detection limit achieved with our technology is at least one million lower than that achieved in routine clinical practice.

Discover

Main Investors

Main Investors
Since our establishment in 2008, we have forged strong relationships with several investors focus on the long-term value creation. They are the heart of our business and together with our scientific promoters (Dr. Javier Tamayo, Dr. Montserrat Calleja and Dr. Priscila Kosaka) help Mecwins to achieve its ambitious goals.

Discover

News and Events

Scientific developments never stop and neither can we. Explore the latest news and recent events in the world of Mecwins.

€4 million injection to help boost Mecwins’s position on the early diagnosis market

By |9 July, 2021|Categories: News|

Mecwins has signed a financial agreement with its investor [...]

Comments Off on €4 million injection to help boost Mecwins’s position on the early diagnosis market

Mecwins Announces Strategic Partnership to Develop a Next Generation Platform for Point of Care (POC) Testing

By |15 June, 2021|Categories: News|

This licensing and co-development agreement leverages Mecwins’ ultrasensitive AVAC [...]

Comments Off on Mecwins Announces Strategic Partnership to Develop a Next Generation Platform for Point of Care (POC) Testing
Go to Top